In particular, CD33 (Siglec-3) is a definitive marker for myeloid leukemias [132], and it has emerged as a vital target in leukemia therapeutics, with its expression levels prognosticating the efficacy of gemtuzumab ozogamicin (GO) in AML treatments. This evidence concerns the gene CD33 and acute myeloid leukemia.